Helix GenoCare is a Genetic Testing Service Provider, emphasizing comprehensive pre- and post-test genetic counseling to ensure accurate test selection and meaningful results. A dedicated team of specialists performs a secondary review of every report, aligning outcomes with the patient's clinical history for maximum accuracy. Helix also serves as a knowledge-sharing platform for clinicians, helping them address genetic queries and enhancing awareness about test utility. The company focuses strongly on screening for common yet impactful conditions where early detection makes a difference—such as prenatal screening for hemoglobinopathies and trisomies, newborn screening, and screening for breast and cervical cancer. Through its SCoPE initiative (Screening, Counseling, and Preventing by Early Diagnosis of Hemoglobinopathies), Helix targets newborns, students, premarital, and prenatal populations. The introduction of Gazelle, an automated point-of-care tool for Beta Thalassemia and Sickle Cell Disease, enhances accessibility. Helix also has a special focus on Molecular Allergology, the 4th Generation In-vitro test for Allergy Diagnostics. Providing CRD based test reports enables a better endo-typing of patients, resulting in personalized care.